10th Annual Innate Killer Summit

Start: Monday, March 3, 2025 9:00AM
End: Wednesday, March 5, 2025 4:30PM

Welcome to the 10th Annual Innate Killer Summit

Celebrating a Decade of Uniting the NK Cell Therapy Community!

As the NK community remains determined as ever to prove the advantages of NK cells, the year of the 'bounce back' now feels within reach. Driven by expansion into autoimmune pipelines, Artiva's $160M IPO marks a sizeable return of investment into this space. It is now business critical for NK developers to capitalize on the new momentum building and showcase clinically validated pipelines to investors to demonstrate the potential of NK therapies and bring long lasting benefit to patients in need.

Returning to San Diego for its 10th Anniversary, the 10th Annual Innate Killer Summit continues to unite long-standing senior pioneers and trailblazers in the NK space. As the only dedicated platform to advancing development of NK engager, NK bispecific, cell therapy, and cytokine-based approaches to the clinic with improved persistence and efficacy, you won't want to miss out.

Join 30+ wave-makers including Indapta Therapeutics, Genentech, Katy Rezvani's Lab, and Artiva Bio as they pave the way to revolutionizing allogeneic and innate immunity treatment.

URLs:
Tickets: https://go.evvnt.com/2676591-0?pid=3698
Brochure: https://go.evvnt.com/2676591-2?pid=3698

Prices:
Full Access Pass: Conference + Focus Day– Vendor Pricing: USD 5197.00,
Full Access Pass: Conference + Workshop Day– Vendor Pricing: USD 5197.00,
Conference Only – Vendor Pricing: USD 3699.00,
Full Access Pass: Conference + Focus Day – Discounted Pricing: USD 3697.00,
Full Access Pass: Conference + Workshop Day – Discounted Pricing: USD 3697.00,
Conference Only – Discounted Pricing: USD 2599.00,
Full Access Pass: Conference + Focus Day– Industry Pricing: USD 4297.00,
Full Access Pass: Conference + Workshop Day– Industry Pricing: USD 4297.00,
Conference Only – Industry Pricing: USD 2999.00

Speakers: Abdulla Berjis, Scientist, University of Pennsylvania, Adil Doganay Duru, Director of Business Development, Glycostem Therapeutics, Anahid Jewett, Professor, University of California Los Angeles, Armin Rath, Senior Vice President and Head of New Product Development, Cytovia Therapeutics, Arnika Wagner, Assistant Professor, Karolinska Institutet, Chris Horan, Chief Technical Operations Officer, Artiva Biotherapeutics, Inc, Dimitra Peppa, Professor, University College London, Dr. Dinesh Kundu, Co-Founder, East Ocyon Bio, Evren Alici, Co-Director - Next Generation NK Cell Competence Center and Research Group Leader, Karolinska Institutet, Fred Aslan, Chief Executive Officer, Artiva Biotherapeutics, Inc, Heather Raymon, Senior Vice President - Research and Early Development, Artiva Biotherapeutics, Inc, Henri Bayle, Chief Scientific Officer, NKILT Therapeutics, Jason Chiang, Professor - Interventional Radiology, University of California Los Angeles, Jason Litten, Chief Medical Officer, Chimeric Therapeutics, Jeffrey Miller, Professor of Medicine, University of Minnesota, Jeffrey Safrit, Senior Director - Infectious Diseases, ImmunityBio, Inc., John Yu, Co-Founder, Apexcella, Karl-Johan Malmberg, Professor, Director The Precision Immunotherapy Alliance, Institute for Cancer Research, Mark Frohlich, Chief Executive Officer, Indapta Therapeutics, Mark Lowdell, Chief Scientific Officer, Inmune Bio, Inc, Matthew Collinson-Pautz, Director - Preclinical and Translational Research, Indapta Therapeutics, Michael Newman, Founder and Chief Scientific Officer, Indaptus Therapeutics, Inc., Neil Sheppard, Director, Research Technologies and Innovation, Center for Cellular Immunotherapies, University of Pennsylvania, Nikolaus Trede, Senior Vice President and Head of Clinical Development, Century Therapeutics, Parveen Shiraz, Medicine, Blood and Marrow Transplantation Instructor, Stanford University, Pinaki Banerjee, Assistant Professor and Director - Rezvani Lab, MD Anderson Cancer Center, Pranay Dogra, Principal Scientist, Genentech, Preet Chaudhary, Founder, Angeles Therapeutics, Raphael Ognar, President and CEO, Co-founder, NKILT Therapeutics, Stefanie Mandl, Chief Scientific Officer, Indapta Therapeutics, Tracy Ryan, Co-Founder, Chief Communications Officer and Inventor, NKore Biotherapeutics, Wei Li, Chief Scientific Officer, CytoLynx, Yana Wang, Senior Director Cell Therapy Oncology Drug Discovery Unit, Takeda Pharmaceutical, Yoshikazu Yonemitsu, Chief Scientific Officer, GAIA Advanced Stem Cells